{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:49Z","timestamp":1792785769866,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":146,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer AG and Loxo Oncology, Inc."},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1093\/annonc\/mdz384","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T15:27:23Z","timestamp":1567610843000},"page":"viii16-viii22","source":"Crossref","is-referenced-by-count":236,"special_numbering":"S8","title":["Identifying patients with NTRK fusion cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"J.P.","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Benayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Hechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ladanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdz384_bb0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1093\/annonc\/mdz384_bb0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdz384_bb0020","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1523\/JNEUROSCI.13-11-04961.1993","article-title":"Neurotrophin-4\/5 is a mammalian-specific survival factor for distinct populations of sensory neurons","volume":"13","author":"Davies","year":"1993","journal-title":"J Neurosci"},{"issue":"5","key":"10.1093\/annonc\/mdz384_bb0025","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0092-8674(91)90396-G","article-title":"The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor","volume":"65","author":"Soppet","year":"1991","journal-title":"Cell"},{"issue":"6314","key":"10.1093\/annonc\/mdz384_bb0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/350158a0","article-title":"Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF","volume":"350","author":"Kaplan","year":"1991","journal-title":"Nature"},{"issue":"6056","key":"10.1093\/annonc\/mdz384_bb0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/319743a0","article-title":"A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences","volume":"319","author":"Martin-Zanca","year":"1986","journal-title":"Nature"},{"issue":"2","key":"10.1093\/annonc\/mdz384_bb0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng0298-184","article-title":"A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma","volume":"18","author":"Knezevich","year":"1998","journal-title":"Nat Genet"},{"issue":"7","key":"10.1093\/annonc\/mdz384_bb0045","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/00000478-200007000-00005","article-title":"Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors","volume":"24","author":"Bourgeois","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1093\/annonc\/mdz384_bb0050","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.5858\/arpa.2010-0351-RS","article-title":"Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression","volume":"135","author":"Vasudev","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1093\/annonc\/mdz384_bb0055","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Skalova","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1093\/annonc\/mdz384_bb0060","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1172\/JCI69766","article-title":"Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers","volume":"123","author":"Ricarte-Filho","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdz384_bb0065","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00037","article-title":"Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion","author":"Farago","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdz384_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer","volume":"109","author":"Pietrantonio","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1093\/annonc\/mdz384_bb0075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.tranon.2018.02.020","article-title":"Gene fusion in malignant glioma: an emerging target for next-generation personalized treatment","volume":"11","author":"Xu","year":"2018","journal-title":"Transl Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz384_bb0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnen\/nly022","article-title":"Targetable gene fusions associate with the IDH wild-type astrocytic lineage in adult gliomas","volume":"77","author":"Ferguson","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"10.1093\/annonc\/mdz384_bb0085","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/PAS.0000000000001055","article-title":"NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma","volume":"42","author":"Chiang","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1093\/annonc\/mdz384_bb0090","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/PAS.0000000000000677","article-title":"ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors","volume":"40","author":"Alassiri","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1093\/annonc\/mdz384_bb0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jmoldx.2016.11.005","article-title":"Identification of NTRK3 fusions in childhood melanocytic neoplasms","volume":"19","author":"Wang","year":"2017","journal-title":"J Mol Diagn"},{"issue":"8","key":"10.1093\/annonc\/mdz384_bb0100","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/PAS.0000000000001070","article-title":"Primary and metastatic melanoma with NTRK fusions","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1093\/annonc\/mdz384_bb0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.2016.69.9751","article-title":"Basket trials in oncology: a trade-off between complexity and efficiency","volume":"35","author":"Cunanan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz384_bb0110","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1093\/annonc\/mdz384_bb0115","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/01.JTO.0000473485.38553.f0","article-title":"Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer","volume":"10","author":"Farago","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz384_bb0120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1093\/annonc\/mdz384_bb0125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1093\/annonc\/mdz384_bb0130","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1093\/annonc\/mdz384_bb0135","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/PAS.0000000000001062","article-title":"Pan-Trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors","volume":"42","author":"Rudzinski","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdz384_bb0140","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/his.13666","article-title":"Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics","volume":"73","author":"Hung","year":"2018","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdz384_bb0145","article-title":"NTRK fusion detection across multiple assays and 33, 997 cases: diagnostic implications and pitfalls","author":"Solomon","year":"2019","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1093\/annonc\/mdz384_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PAS.0b013e318231542a","article-title":"Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity","volume":"36","author":"Connor","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1093\/annonc\/mdz384_bb0155","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov"},{"issue":"33","key":"10.1093\/annonc\/mdz384_bb0160","doi-asserted-by":"crossref","first-page":"55353","DOI":"10.18632\/oncotarget.19512","article-title":"Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient","volume":"8","author":"Milione","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1093\/annonc\/mdz384_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/PAS.0000000000000537","article-title":"Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion","volume":"40","author":"Skalova","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdz384_bb0170","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/JTO.0000000000000444","article-title":"ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice","volume":"10","author":"Martin","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz384_bb0175","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jmoldx.2019.03.008","article-title":"Detection of tumor NTRK gene fusions to identify patients who may benefit from TRK inhibitor therapy","volume":"21","author":"Hsiao","year":"2019","journal-title":"J Mol Diagn"},{"issue":"2","key":"10.1093\/annonc\/mdz384_bb0180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/gcc.20937","article-title":"Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data","volume":"51","author":"Wang","year":"2012","journal-title":"Genes Chromosom Cancer"},{"issue":"24","key":"10.1093\/annonc\/mdz384_bb0185","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1158\/1078-0432.CCR-12-0838","article-title":"Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions","volume":"18","author":"Suehara","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1093\/annonc\/mdz384_bb0190","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdz384_bb0195","author":"U.S. Food and Drug Administration"},{"issue":"1","key":"10.1093\/annonc\/mdz384_bb0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1093\/annonc\/mdz384_bb0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jmoldx.2015.10.002","article-title":"A multiplexed amplicon approach for detecting gene fusions by next-generation sequencing","volume":"18","author":"Beadling","year":"2016","journal-title":"J Mol Diagn"},{"issue":"4","key":"10.1093\/annonc\/mdz384_bb0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/cancers10040105","article-title":"Inhibiting TRK proteins in clinical cancer therapy","volume":"10","author":"Lange","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1093\/annonc\/mdz384_bb0215","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"10.1093\/annonc\/mdz384_bb0220","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41379-018-0175-7","article-title":"Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma","volume":"32","author":"Zhu","year":"2019","journal-title":"Mod Pathol"},{"issue":"15","key":"10.1093\/annonc\/mdz384_bb0225","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdz384_bb0230","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jmoldx.2017.05.006","article-title":"Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors","volume":"19","author":"Reeser","year":"2017","journal-title":"J Mol Diagn"},{"issue":"7","key":"10.1093\/annonc\/mdz384_bb0235","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/PAI.0000000000000360","article-title":"Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing","volume":"25","author":"Murphy","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"10.1093\/annonc\/mdz384_bb0240","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/0008-5472.CAN-18-3126","article-title":"Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF\/KRAS are enriched for targetable kinase fusions","volume":"79","author":"Cocco","year":"2019","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdz384_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","author":"Marchio","year":"2019","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz384_bb0250","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1093\/annonc\/mdz384_bb0255","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz384_bb0260","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419551183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419551183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/Supplement_8\/viii16\/30959888\/mdz384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/Supplement_8\/viii16\/30959888\/mdz384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T12:10:54Z","timestamp":1585224654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419551183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":51,"alternative-id":["S0923753419551183"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz384","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}